Drug Profile
Dalosirvat - Biosplice Therapeutics
Alternative Names: SM-04554Latest Information Update: 19 Apr 2021
Price :
$50
*
At a glance
- Originator Samumed
- Developer Biosplice Therapeutics
- Class 2 ring heterocyclic compounds; Dioxanes; Ketones; Skin disorder therapies; Small molecules
- Mechanism of Action Wnt signalling pathway stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Alopecia
Most Recent Events
- 15 Apr 2021 Samumed is now called Biosplice Therapeutics
- 05 Apr 2021 Dalosirvat is still in phase II/III clinical trial in Alopecia (In adults) in Turkey (Topical) (NCT03742518)
- 19 Feb 2021 Chemical structure information added